Atrium Therapeutics, Inc. cash flow to debt ratio of -1.12K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Atrium Therapeutics, Inc.'s free cash flow has increased -86.17% from $-307.94M last year to $-42.57M, signaling increasing performance

Atrium Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Atrium Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Atrium Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Interest expense is not separately reported in Atrium Therapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Atrium Therapeutics, Inc.'s profit margin has increased (-89.33%) in the last year from -2.96K% to -315.71%, signaling increasing performance

Atrium Therapeutics, Inc.'s short-term assets of $272.85M exceed its short-term liabilities of $41.80M

Atrium Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Atrium Therapeutics, Inc.'s return on equity of -29.67%, is lower than 15.00%, indicating bad performance

Atrium Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Atrium Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Atrium Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Atrium Therapeutics, Inc. has negative free cash flow, indicating cash burn

Atrium Therapeutics, Inc.'s yearly earnings has increased -76.21% since last year from $-322.30M to $-76.68M, signaling increasing performance

Atrium Therapeutics, Inc.'s yearly revenue has increased 72.11% since last year from $10.90M to $18.75M, signaling increasing performance

ROIC -23.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Atrium Therapeutics, Inc.'s 3-year revenue CAGR of 26.38% is positive, indicating growing revenue over the past 3 years

Atrium Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Atrium Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Atrium Therapeutics, Inc. has insufficient data to evaluate this check.

Atrium Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Atrium Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Atrium Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Atrium Therapeutics, Inc. is overvalued relative to its fair value price of -408.41 based on Earnings Fair Value model

Atrium Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Atrium Therapeutics, Inc. has a price-to-book ratio of 0.89x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Atrium Therapeutics, Inc. has a price-to-sales ratio of 10.20x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue